(11) 98705-3426
TrademarkIQ íconeTrademarkIQ
Voltar para busca
Dado oficial do USPTO

ASCENTAGE

Sabia que essa marca já está registrada no Estados Unidos?

Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.

Active USPTO registrationTipo: MistaEscritório: US

Snapshot rápido

ASCENTAGE

ST13

US500000099113144

Classe

5

Pedido

99113144

Registro

8227611

Diagnóstico de risco e oportunidade

Leitura executiva para decisão de naming, protocolo e monitoramento.

Atenção: há risco ativo

Situação USPTO

Active USPTO registration

Tipo de processo

Pedido e registro

Eventos registrados

23

Atualização mais recente

28/04/2026

Classificação

Registrada

Tipo de marca

Mista

Classes Nice

5

Data de depósito

31/03/2025

Data de registro

28/04/2026

Data de expiração

-

Ação recomendada

Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.

Próximo passo

Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.

Dados completos do processo

Campos estruturados da autoridade responsável e do histórico oficial.

Data da situação

28/04/2026

Última transação

28/04/2026

Escritório responsável

United States Patent and Trademark Office

Código da situação

700

Cadastro oficial

Principal Register

Fundamento do pedido

Intent to use, Foreign priority

Código do desenho

3

Tipo de titular

99

Localização do titular

JIANGSU, CN

Examinador

SCHLEGELMILCH, JONATHON A

Unidade examinadora

L80

Localização atual

FILE REPOSITORY (FRANCONIA)

Descrição da marca

The mark consists of the word Ascentage in a stylized font with two arc-shaped lines appearing above and underneath the first "A", and the center line of the first "A" appearing as a diagonal line extending above the letters "sce" of Ascentage.

Titulares e representantes

Titulares

ASCENTAGE PHARMA (SUZHOU) CO., LTD.

Representantes

Kathryn E. Smith WOOD HERRON & EVANS LLP

Classificação técnica

Classes Nice

Classe 5

Códigos Vienna

Sem códigos Vienna disponíveis.

Produtos e serviços

Classe 5

Chemical preparations for medical purposesfor use in the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; drugs sold in bulkfor use in the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; biochemical medicines for use in the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; diagnostic preparations for medical purposes; diagnostic biomarker reagents for medical purposes; medicines for human purposes for use in the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; pharmaceutical preparations for the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; chemico-pharmaceutical preparations for the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; drugs for medical purposes in the nature of prescription apoptosis targeted compoundsnext-generation kinase inhibitors and senolytic drugs; biological preparations for medical purposesbiological preparations for the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; chemical preparations for pharmaceutical purposesfor use in the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; radioactive substances for medical purposes; gases for medical purposesnitric oxide for medical purposes; chemical conductors for electrocardiograph electrodes; semen for artificial insemination; disinfectants; solutions for contact lenses; media for bacteriological cultures for medical purposes; medicated sweets; dietetic preparations adapted for medical purposes; depuratives for the body; diagnostic preparations for veterinary purposes; pesticides; sanitary napkins; cotton for medical purposes; dental abrasives; diapers for pets

Publicações

Histórico de despachos e eventos da marca no USPTO.

23 publicações encontradas

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

28/04/2026

R.PR

REGISTERED-PRINCIPAL REGISTER

28/04/2026

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

10/03/2026

PUBO

PUBLISHED FOR OPPOSITION

10/03/2026

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

04/03/2026

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

12/02/2026

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

11/02/2026

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

11/02/2026

ERSI

TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED

11/02/2026

GNS3

NOTIFICATION OF LETTER OF SUSPENSION E-MAILED

12/01/2026

GNSL

LETTER OF SUSPENSION E-MAILED

12/01/2026

CNSL

SUSPENSION LETTER WRITTEN

12/01/2026

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

05/12/2025

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

05/12/2025

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

05/12/2025

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

10/09/2025

GNRT

NON-FINAL ACTION E-MAILED

10/09/2025

CNRT

NON-FINAL ACTION WRITTEN

10/09/2025

DOCK

ASSIGNED TO EXAMINER

28/08/2025

MDSC

NOTICE OF DESIGN SEARCH CODE E-MAILED

14/08/2025

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

14/08/2025

MAFR

APPLICATION FILING RECEIPT MAILED

31/03/2025

NWAP

NEW APPLICATION ENTERED

31/03/2025

Proteção contínua da sua marca

Seja avisado a cada novo depósito que ameace ASCENTAGE ou a sua marca.

Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.